Literature DB >> 12052710

Mono-N-terminal poly(ethylene glycol)-protein conjugates.

Olaf Kinstler1, Graham Molineux, Michael Treuheit, David Ladd, Colin Gegg.   

Abstract

A site-directed method of joining proteins to poly(ethylene glycol) is presented which allows for the preparation of essentially homogeneous PEG-protein derivatives with a single PEG chain conjugated to the amine terminus of the protein. This selectivity is achieved by conducting the reductive alkylation of proteins with PEG-aldehydes at lower pH. Working examples demonstrating the application of this method to improve the delivery characteristics and therapeutic value of several proteins are provided.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052710     DOI: 10.1016/s0169-409x(02)00023-6

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  41 in total

Review 1.  Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.

Authors:  Suphiya Parveen; Sanjeeb K Sahoo
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  Polymer-drug conjugates: recent development in clinical oncology.

Authors:  Chun Li; Sidney Wallace
Journal:  Adv Drug Deliv Rev       Date:  2008-02-08       Impact factor: 15.470

Review 3.  Applications of orthogonal "click" chemistries in the synthesis of functional soft materials.

Authors:  Rhiannon K Iha; Karen L Wooley; Andreas M Nyström; Daniel J Burke; Matthew J Kade; Craig J Hawker
Journal:  Chem Rev       Date:  2009-11       Impact factor: 60.622

4.  Screening of reducing agents for the PEGylation of recombinant human IL-10.

Authors:  Alexandre Ambrogelly; Collette Cutler; Brittany Paporello
Journal:  Protein J       Date:  2013-06       Impact factor: 2.371

5.  The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?

Authors:  Christian Lubich; Peter Allacher; Maurus de la Rosa; Alexander Bauer; Thomas Prenninger; Frank Michael Horling; Jürgen Siekmann; Johannes Oldenburg; Friedrich Scheiflinger; Birgit Maria Reipert
Journal:  Pharm Res       Date:  2016-06-07       Impact factor: 4.200

6.  Continuous flow microreactor for protein PEGylation.

Authors:  P Madadkar; P R Selvaganapathy; R Ghosh
Journal:  Biomicrofluidics       Date:  2018-08-20       Impact factor: 2.800

Review 7.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

8.  Optimized clinical performance of growth hormone with an expanded genetic code.

Authors:  Ho Cho; Tom Daniel; Ying Ji Buechler; David C Litzinger; Zhenwei Maio; Anna-Maria Hays Putnam; Vadim S Kraynov; Bee-Cheng Sim; Stuart Bussell; Tsotne Javahishvili; Sami Kaphle; Guillermo Viramontes; Mike Ong; Stephanie Chu; G C Becky; Ricky Lieu; Nick Knudsen; Paola Castiglioni; Thea C Norman; Douglas W Axelrod; Andrew R Hoffman; Peter G Schultz; Richard D DiMarchi; Bruce E Kimmel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

9.  An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects.

Authors:  Kwang-Hee Shin; Kyoung Soo Lim; Howard Lee; In-Jin Jang; Kyung-Sang Yu
Journal:  Invest New Drugs       Date:  2014-01-28       Impact factor: 3.850

10.  PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution.

Authors:  Ryan G Soderquist; Erin D Milligan; Evan M Sloane; Jacqueline A Harrison; Klarika K Douvas; Joseph M Potter; Travis S Hughes; Raymond A Chavez; Kirk Johnson; Linda R Watkins; Melissa J Mahoney
Journal:  J Biomed Mater Res A       Date:  2009-12       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.